ENSC / Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applyi more_horizontal

Featured Presentation on ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose' SAN DIEGO, CA / ACCES more_horizontal

Clinical-stage biotechnology firm Ensysce Biosciences (NASDAQ: ENSC ) skyrocketed sharply on Tuesday, with shares at one point gaining 50% before sett more_horizontal

~ Global QUOTIENT LIFE SCIENCES Webinar Today, April 19, 2023 at 11:30am ET ~ SAN DIEGO, CA / ACCESSWIRE / April 19, 2023 / Ensysce Biosciences, Inc. more_horizontal

Ensysce Biosciences, Inc. (ENSC) CEO Dr. Lynn Kirkpatrick on Corporate Update Call (Transcript) more_horizontal

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage b more_horizontal

Ensysce Biosciences is using its proprietary Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistance to develop tamper-proof, powerful opio more_horizontal

Ensysce Biosciences is using its proprietary Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistance to develop tamper-proof, powerful opio more_horizontal